101 related articles for article (PubMed ID: 26561977)
1. Biomarker Development for Intraductal Papillary Mucinous Neoplasms Using Multiple Reaction Monitoring Mass Spectrometry.
Kim Y; Kang M; Han D; Kim H; Lee K; Kim SW; Kim Y; Park T; Jang JY; Kim Y
J Proteome Res; 2016 Jan; 15(1):100-13. PubMed ID: 26561977
[TBL] [Abstract][Full Text] [Related]
2. High-density and targeted glycoproteomic profiling of serum proteins in pancreatic cancer and intraductal papillary mucinous neoplasm.
Aronsson L; Andersson R; Bauden M; Andersson B; Bygott T; Ansari D
Scand J Gastroenterol; 2018 Dec; 53(12):1597-1603. PubMed ID: 30509115
[TBL] [Abstract][Full Text] [Related]
3. Utility of promoter hypermethylation in malignant risk stratification of intraductal papillary mucinous neoplasms.
Chhoda A; Sharma A; Sailo B; Tang H; Ruzgar N; Tan WY; Ying L; Khatri R; Narayanan A; Mane S; De Kumar B; Wood LD; Iacobuzio-Donahue C; Wolfgang CL; Kunstman JW; Salem RR; Farrell JJ; Ahuja N
Clin Epigenetics; 2023 Feb; 15(1):28. PubMed ID: 36803844
[TBL] [Abstract][Full Text] [Related]
4. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms.
Rebours V; Le Faouder J; Laouirem S; Mebarki M; Albuquerque M; Camadro JM; Léger T; Ruszniewski P; Lévy P; Paradis V; Bedossa P; Couvelard A
Pancreatology; 2014; 14(2):117-24. PubMed ID: 24650966
[TBL] [Abstract][Full Text] [Related]
5. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer.
Ilies M; Sappa PK; Iuga CA; Loghin F; Gesell Salazar M; Weiss FU; Beyer G; Lerch MM; Völker U; Mayerle J; Hammer E
Clin Chim Acta; 2018 Feb; 477():127-134. PubMed ID: 29221926
[TBL] [Abstract][Full Text] [Related]
6. Validation of a nomogram for predicting the probability of carcinoma in patients with intraductal papillary mucinous neoplasm in 180 pancreatic resection patients at 3 high-volume centers.
Shimizu Y; Yamaue H; Maguchi H; Yamao K; Hirono S; Osanai M; Hijioka S; Kanemitsu Y; Sano T; Senda Y; Bhatia V; Yanagisawa A
Pancreas; 2015 Apr; 44(3):459-64. PubMed ID: 25423557
[TBL] [Abstract][Full Text] [Related]
7. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
8. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
9. Possibility of detecting intraductal papillary mucinous neoplasms using metabolite biomarkers for pancreatic cancer.
Nakano R; Nishiumi S; Kobayashi T; Ikegawa T; Kodama Y; Yoshida M
Biomark Med; 2020 Jul; 14(11):1009-1020. PubMed ID: 32940075
[No Abstract] [Full Text] [Related]
10. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma.
Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586
[TBL] [Abstract][Full Text] [Related]
11. Marker Identification of the Grade of Dysplasia of Intraductal Papillary Mucinous Neoplasm in Pancreatic Cyst Fluid by Quantitative Proteomic Profiling.
Do M; Kim H; Shin D; Park J; Kim H; Han Y; Jang JY; Kim Y
Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32842508
[TBL] [Abstract][Full Text] [Related]
12. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms.
Do M; Han D; Wang JI; Kim H; Kwon W; Han Y; Jang JY; Kim Y
Clin Proteomics; 2018; 15():17. PubMed ID: 29713252
[TBL] [Abstract][Full Text] [Related]
14. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
15. A new panel of pancreatic cancer biomarkers discovered using a mass spectrometry-based pipeline.
Liu X; Zheng W; Wang W; Shen H; Liu L; Lou W; Wang X; Yang P
Br J Cancer; 2017 Dec; 117(12):1846-1854. PubMed ID: 29123261
[TBL] [Abstract][Full Text] [Related]
16. Proteomic assessment of markers for malignancy in the mucus of intraductal papillary mucinous neoplasms of the pancreas.
Corcos O; Couvelard A; Dargère D; Sauvanet A; Hammel P; Paradis V; Lévy P; Ruszniewski P; Bedossa P
Pancreas; 2012 Mar; 41(2):169-74. PubMed ID: 22076567
[TBL] [Abstract][Full Text] [Related]
17. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
18. Extrapancreatic malignancies in patients with intraductal papillary mucinous neoplasm of the pancreas: prevalence, associated factors, and comparison with patients with other pancreatic cystic neoplasms.
Yoon WJ; Ryu JK; Lee JK; Woo SM; Lee SH; Park JK; Kim YT; Yoon YB
Ann Surg Oncol; 2008 Nov; 15(11):3193-8. PubMed ID: 18784959
[TBL] [Abstract][Full Text] [Related]
19. Protein profiling in pancreatic juice for detection of intraductal papillary mucinous neoplasm of the pancreas.
Shirai Y; Sogawa K; Yamaguchi T; Sudo K; Nakagawa A; Sakai Y; Ishihara T; Sunaga M; Nezu M; Tomonaga T; Miyazaki M; Saisho H; Nomura F
Hepatogastroenterology; 2008; 55(86-87):1824-9. PubMed ID: 19102401
[TBL] [Abstract][Full Text] [Related]
20. [Diagnosis and differential diagnosis of intraductal papillary mucinous neoplasm of pancreas].
Ji Y; Tan YS; Zhu XZ; Zeng HY; Kuang TT; Jin DY
Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):77-81. PubMed ID: 16630480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
